Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities in the United States. It operates through Acute Care Hospital Services and Behavioral Health Care Services segments. The company’s hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric, pharmacy, and/or behavioral health services. It also provides commercial health insurance services; capital resources; and various management services, including central purchasing, information services, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Market Outlook | Analyst price targets range from $227 to $263, reflecting confidence in UHS's ability to navigate healthcare policy changes while leveraging margin expansion opportunities across its business segments. |
Strategic Vision | Explore UHS's shareholder-focused approach through a $1.759 billion stock repurchase program representing 13% of market cap, balanced with strategic development initiatives for long-term growth. |
Segment Dynamics | Delve into UHS's contrasting segment performance where acute care shines with 43% same-store EBITDA growth while behavioral health faces persistent volume challenges despite pricing strength. |
Financial Resilience | UHS demonstrates robust performance with Q3 adjusted EBITDA exceeding estimates by 9%, leading to raised 2025 guidance despite underlying operational challenges masked by one-time payments. |
Metrics to compare | UHS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipUHSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 7.4x | 19.9x | −0.5x | |
PEG Ratio | 0.20 | 3.61 | 0.00 | |
Price / Book | 1.5x | 3.8x | 2.6x | |
Price / LTM Sales | 0.6x | 1.3x | 3.2x | |
Upside (Analyst Target) | 32.5% | 38.5% | 47.6% | |
Fair Value Upside | Unlock | 17.3% | 6.1% | Unlock |